Utilising an interleukin-12 plasmid: a novel COVID-19 vaccine 13 May 2020 | By Victoria Rees (Drug Target Review) Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
Begin with the end in mind: designing synthetic antibiotics with a universal mechanism of action 6 May 2020 | By Victoria Rees (Drug Target Review) James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
Intravenous immunoglobulins, hyperimmunes and pandemic viruses 4 May 2020 | By Hannah Balfour (Drug Target Review) David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Developing respiratory therapeutics for prophylaxis and treatment 30 April 2020 | By Hannah Balfour (Drug Target Review) Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Cytokine storms: a major killer in patients with severe COVID-19 infection 27 April 2020 | By Professor Saad Shakir (Drug Safety Research Unit) Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
Natural peptides versus COVID-19 25 April 2020 | By Oleg Kit (Interregional Academy of Personnel Management), Yuriy Kit (National Academy of Science of Ukraine) Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
Histone deacetylase 2 (HDAC2) regulates pathological response of inflammatory monocytes: a potential target of adjuvant therapies for COVID-19 infection 23 April 2020 | By Dr Rosa Tordera (University of Navarra), Maria Cortes (University of Navarra) Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes.
Developing immunotherapies for hard-to-treat cancers 23 April 2020 | By Hannah Balfour (Drug Target Review) Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
High-throughput screening for antibody-based drugs 16 April 2020 | By Victoria Rees (Drug Target Review) A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
The coronavirus as a personalised enemy of mankind 15 April 2020 | By Dr Ulrich Kutschera (University of Kassel) How has evolution led us to the point where humans are an ideal host for SARS-CoV-2, the virus that causes the COVID-19 coronavirus?
Mesenchymal stem cells secretome as a prospective therapeutic option for COVID-19 patients 13 April 2020 | By Avinash Kharat (Dr D Y Patil Vidyapeeth), Avinash Sanap ( Dr D Y Patil Vidyapeeth), Dr Ramesh Bhonde (Dr D Y Patil Vidyapeeth), Supriya Kheur (Dr D Y Patil Vidyapeeth) Researchers propose using mesenchymal stem cells to counter the pro-inflammatory cytokines associated with COVID-19 coronavirus symptoms.
Refreshing how we approach neuroscience with a novel screening technology 9 April 2020 | By Hannah Balfour (Drug Target Review) Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
Gender-specific coronavirus infections in the light of evolution 9 April 2020 | By Dr Ulrich Kutschera (University of Kassel) Dr Kutschera discusses the differences between males and females in relation to infection from the COVID-19 coronavirus.
COVID-19 and big pharma: what are 15 leading companies doing to develop a coronavirus vaccine? 9 April 2020 | By Victoria Rees (Drug Target Review) A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Predicting which diabetes treatments will reach clinical trials 7 April 2020 | By Victoria Rees (Drug Target Review) Researchers at MIT have developed a mathematical model that can calculate whether diabetes treatments in pre-clinical trials will be successful in humans.
